Cue Biopharma Reports Q2 2025 Earnings: Collaboration Revenue Exceeds Estimate, Net Loss Narrows

Cue Biopharma Inc reported Q2 2025 earnings with EPS of -$0.09, beating estimates. Collaboration revenue surpassed forecasts at $3.0 million. The company faces challenges with a net loss of $8.5 million due to ongoing R&D investments. Cue Biopharma's strategic collaboration with Boehringer Ingelheim and successful public offering provide a solid foundation for future advancements in its clinical programs.

Cue Biopharma Inc. (CUE) reported its second-quarter 2025 earnings, with an earnings per share (EPS) of -$0.09, which beat the Zacks Consensus Estimate of -$0.13 [1]. This marks a significant improvement from the year-ago period, when the company reported an EPS of -$0.20. The company also surpassed revenue estimates, with $2.95 million in revenues, a 47.70% increase over the year-ago period and a 47.70% beat over the Zacks Consensus Estimate [1].

Despite the positive revenue performance, Cue Biopharma faced challenges with a net loss of $8.5 million for the quarter. This loss was primarily driven by ongoing research and development (R&D) investments, which totaled $7.9 million, a reduction of $1.6 million compared to the previous quarter [2]. The company's strategic collaboration with Boehringer Ingelheim contributed $3.0 million in collaboration revenue, which surpassed forecasts and helped offset some of the R&D expenses [2].

One of the key highlights of the quarter was the positive FDA feedback on CUE-401's Pre-IND submission for autoimmune disease treatment and the impressive clinical results from the Phase 1 trial of CUE-101 in HPV+ head and neck cancer, showing a 50% overall response rate and 32-month median overall survival [2]. These developments provide a solid foundation for future advancements in the company's clinical programs.

Cue Biopharma also strengthened its financial position by raising $20 million through a public offering, which extended its cash runway. As of June 30, 2025, the company had $27.49 million in cash and equivalents, up from $22.46 million at year-end 2024 [2].

Looking ahead, the company's near-term stock performance is expected to be in line with the market, as indicated by the Zacks Rank #3 (Hold) [1]. Investors should closely monitor the company's earnings outlook and future estimate revisions for further insights into the stock's potential.

References:
[1] https://finance.yahoo.com/news/cue-biopharma-inc-cue-reports-211002021.html
[2] https://www.stocktitan.net/news/CUE/cue-biopharma-reports-second-quarter-2025-financial-results-and-ibm7evc1qtda.html